Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents

This 2005 paper in *Neurochemical Research* is one of the cleanest Western-indexed mechanism studies of Semax. The authors — a Moscow-Tampere collaboration anchored by Myasoedov's group at the V.N. Orekhovich Institute of Biomedical Chemistry — examined how Semax administration alters brain monoamine systems in rats, using HPLC measurement of striatal tissue content of dopamine and its metabolites and the serotonin metabolite 5-HIAA. Two findings frame the modern mechanistic understanding of Semax. First, Semax raised striatal 5-HIAA by approximately 25% at two hours post-injection, with metabolite levels reaching 180% of baseline at one to four hours — consistent with increased serotonin turnover. Second, Semax administration alone did not change dopamine concentrations; however, Semax pretreatment 20 minutes before D-amphetamine substantially amplified the amphetamine-induced rise in extracellular dopamine and the corresponding locomotor activation. The combined picture frames Semax as a neuromodulatory peptide that influences serotonergic turnover directly and amplifies dopaminergic responses to other stimuli, rather than acting as a direct dopamine releaser on its own.

This is a rodent neurochemistry paper, not a clinical trial. The findings characterize acute neurotransmitter responses in striatal tissue and locomotor behavior in healthy rats; translation to human cognitive performance, post-stroke rehabilitation, or chronic dosing requires additional inferential steps not made in this paper. The dopamine-amplification finding is mechanistically interesting and clinically relevant — it implies a theoretical pharmacodynamic interaction between Semax and stimulant medications that practitioners should weight — but the magnitude and reproducibility in humans is not characterized. The authors are among the principal investigators of the Russian Semax program, which is the standard situation for the field but should be weighted alongside the otherwise rigorous methods. The paper does not attempt to dissociate the contributions of the parent ACTH(4-7) fragment from the protective Pro-Gly-Pro tail; subsequent work has shown the tail itself carries activity, but that decomposition is not in this paper.